

Resource Summary Report

Generated by [RRID](#) on Sep 20, 2026

Molecular Devices: SpectraMax M5 Multimode Plate Reader

RRID:SCR_020300

Type: Tool

Proper Citation

Molecular Devices: SpectraMax M5 Multimode Plate Reader (RRID:SCR_020300)

Resource Information

URL: <https://us.vwr.com/store/product/8099539/spectramax-m5-m5e-multimode-plate-reader-molecular-devices#stiboGrid>

Proper Citation: Molecular Devices: SpectraMax M5 Multimode Plate Reader (RRID:SCR_020300)

Description: Microplate Reader delivers single mode reader performance and can be equipped to read volumes as low as 2uL in one multimode reader package. The dual monochromator optics allow the widest range of applications to be utilized for bio research and drug discovery applications, all without the need to change filters. For fluorescence intensity, time resolved fluorescence, and fluorescence polarization assays, the SpectraMax M5 Microplate Reader optical design provides the highest level of flexibility. Users can select from top or bottom read modes for improved sensitivity for solution and cell-based assays. Assays can be better optimized by scanning across a range of wavelengths in increments as small as 1 nm. Up to 4 wavelength pairs can be read in one protocol for endpoint and kinetic measurements, allowing for fast setup of FRET and TR-FRET assays. For luminescence, the SpectraMax M5 Microplate Reader utilizes a dedicated luminescence photomultiplier tube (PMT), providing the user the maximum signal and lowest background possible for glow luminescence reporter gene assays. The SpectraMax M5 utilizes a single monochromator design for UV/VIS Absorbance, allowing the user to maximize sensitivity and tunability, and also uses patented PathCheck Pathlength Measurement Technology: the only temperature independent pathlength correction for microplates. The M5 can read volumes down to 2uL with the uMax Low Volume Plate.

Resource Type: instrument resource

Keywords: Molecular Devices, Multimode Plate Reader, Instrument Equipment, USEDit

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_020300.pdf

Resource Name: Molecular Devices: SpectraMax M5 Multimode Plate Reader

Resource ID: SCR_020300

Alternate IDs: Model_Number_SpectraMax M5

Record Creation Time: 20220129T080349+0000

Record Last Update: 20260919T195432+0000

Ratings and Alerts

No rating or validation information has been found for Molecular Devices: SpectraMax M5 Multimode Plate Reader.

No alerts have been found for Molecular Devices: SpectraMax M5 Multimode Plate Reader.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Adhikary U, et al. (2026) Cancer Susceptibility to Stapled Oncolytic Peptides Is Dictated by Membrane Cholesterol and Inflammatory Signaling. Cancer research, 86(11), 2810.

Favours E, et al. (2026) Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(14), 3031.

Ma B, et al. (2026) MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer. Molecular cancer research : MCR.

Swain S, et al. (2025) Low-Glucose Culture Conditions Bias Neuronal Energetics Towards Oxidative Phosphorylation. Journal of neurochemistry, 169(6), e70125.

Liu C, et al. (2025) Chronic Stress Stimulates Protumor Macrophage Polarization to Propel Lung Cancer Progression. Cancer research, 85(13), 2429.

Kenny HA, et al. (2025) Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Molecular

cancer therapeutics, 24(8), 1252.

Kanaoka D, et al. (2024) FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1 γ to Activate p53 and Inhibit NF κ B Signaling. *Cancer research communications*, 4(2), 312.

Sui M, et al. (2024) The role of Testis-Specific Protein Y-encoded-Like 2 in kidney injury. *iScience*, 27(5), 109594.

Xing X, et al. (2023) Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy. *Cell reports. Medicine*, 4(12), 101315.

Sutton MS, et al. (2023) Vaccine elicitation and structural basis for antibody protection against alphaviruses. *Cell*, 186(12), 2672.